Weisenthal Cancer Group 16512 Burke Ln, Huntington Beach, CA 92647 7145962100 (phone), 7145962110 (fax)
Education:
Medical School University of Michigan Medical School Graduated: 1975
Languages:
English
Description:
Dr. Weisenthal graduated from the University of Michigan Medical School in 1975. He works in Huntington Beach, CA and specializes in Hematology/Oncology.
Microaggregates which mimic the native environment of cells contained in biopsied tissue are used to assess and predict the effects of various treatments on the viability of cell types contained in the microaggregate.
Efficient Well Being Assessment And Improved Treatment Protocol
Methods to appraise general health and to assess the effectiveness of therapeutic agents are disclosed. These methods can be performed on blood samples or other bodily fluids and comprise effecting cell death of endothelial cells, staining the dead cells and observing them microscopically. In addition, the invention is directed to combination treatments for neoplastic diseases or other conditions characterized by unwanted angiogenesis by administering an antiangiogenesis agent while maintaining nontoxic levels of ethanol and/or DMSO in the blood.
Method To Detect Endothelial Cell Massive Calcium Accumulation Death
Stains that are specific for calcium ion are used to assess and predict the effects of various treatments on the viability of cell types contained in a sample, wherein said stain detects endothelial cells that have massive calcium accumulation death.
A method for detecting the sensitivity of tumor cells to immune effector substances by using an assay that distinguishes living tumor cells from dead cells in mixed populations of cells. Acquired resistance to immune effectors used in therapy may be determined and used to identify methods to circumvent such resistance using the method.
Immunopotentiating Protocol For Chemotherapy-Responsive Tumors
Immunopotentiating compositions which are useful in causing tumor necrosis and/or regression in subjects who have previously received successful therapy which destroys tumors and stimulates cytotoxic macrophages are described. The immunopotentiators are administered at a time when formation of macrophages specifically cytotoxic for the tumor have been generated by previous therapy.